Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited

XSSC:600329 Stock Report

Market Cap: CN¥21.4b

Tianjin Pharmaceutical Da Ren Tang Group Valuation

Is 600329 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 600329 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 600329 (CN¥32.16) is trading below our estimate of fair value (CN¥111.71)

Significantly Below Fair Value: 600329 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 600329?

Key metric: As 600329 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 600329. This is calculated by dividing 600329's market cap by their current earnings.
What is 600329's PE Ratio?
PE Ratio26.6x
EarningsCN¥932.37m
Market CapCN¥21.41b

Price to Earnings Ratio vs Peers

How does 600329's PE Ratio compare to its peers?

The above table shows the PE ratio for 600329 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average25.3x
600062 China Resources Double-Crane PharmaceuticalLtd
15.7x16.6%CN¥21.2b
600535 Tasly Pharmaceutical Group
24.5x22.7%CN¥21.6b
300558 Betta Pharmaceuticals
47x26.7%CN¥21.6b
600380 Joincare Pharmaceutical Group IndustryLtd
14.2x11.8%CN¥20.8b
600329 Tianjin Pharmaceutical Da Ren Tang Group
26.6x20.8%CN¥21.4b

Price-To-Earnings vs Peers: 600329 is expensive based on its Price-To-Earnings Ratio (26.6x) compared to the peer average (25.3x).

Price to Earnings Ratio vs Industry

How does 600329's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
600329 26.6xIndustry Avg. 29.9xNo. of Companies31PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 600329 is good value based on its Price-To-Earnings Ratio (26.6x) compared to the CN Pharmaceuticals industry average (29.9x).

Price to Earnings Ratio vs Fair Ratio

What is 600329's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

600329 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio26.6x
Fair PE Ratio28.9x

Price-To-Earnings vs Fair Ratio: 600329 is good value based on its Price-To-Earnings Ratio (26.6x) compared to the estimated Fair Price-To-Earnings Ratio (28.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Dong-E-E-JiaoLtd

CN¥36.7b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥57.18

7D

-1.8%

1Y

13.3%

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.20

7D

-3.1%

1Y

-24.5%

Hunan Jiudian Pharmaceutical

CN¥11.8b

Researches, develops, produces, and sells pharmaceutical products in China and internationally.

300705

CN¥23.80

7D

-1.8%

1Y

12.8%